Many clinical trials have reported that omapatrilat, which inhibits various proteases including neprilysin and angiotensin-converting enzyme (ACE), may increase the risk of angioedema when it is used to treat hypertension [10, 11]. Here, ACE is linked to hypertensive disorder.